GeneDx Holdings (WGS) Free Cash Flow (2020 - 2026)

GeneDx Holdings has disclosed Free Cash Flow across 7 years of filings, most recently posting -$38.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 579.94% year-over-year to -$38.3 million; the TTM figure through Mar 2026 stood at -$19.3 million (down 208.94% YoY), while the FY2025 annual figure was $27.0 million, up 186.81% from the prior year.
• Free Cash Flow retreated to -$38.3 million in Q1 2026, from $5.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for WGS reached as high as $8.0 million in Q1 2025 and fell as low as -$92.1 million in Q3 2022.
• The 5-year median for Free Cash Flow is -$28.8 million (2023), against an average of -$31.9 million.
• Annual changes were most pronounced in 2025 — Free Cash Flow jumped 258.55% — and 2026, when it plunged 579.94%.
• A 5-year view of Free Cash Flow shows it stood at -$58.2 million in 2022, then surged by 50.53% to -$28.8 million in 2023, then surged by 88.39% to -$3.3 million in 2024, then jumped by 258.55% to $5.3 million in 2025, then sank by 823.89% to -$38.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$38.3 million, $5.3 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.